GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
June 27, 2024 09:15 ET
|
GT Biopharma, Inc.
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550...
New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease
June 20, 2024 08:00 ET
|
Hemex Health
PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
June 14, 2024 08:03 ET
|
Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer. Earlier this year, scientists from Columbia University in New...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
June 11, 2024 09:00 ET
|
GRI Bio, Inc.
Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology...
Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path to More Personalized Treatments - A Free Webinar from the Brain & Behavior Research Foundation
June 03, 2024 13:19 ET
|
Brain & Behavior Research Foundation
New York, June 03, 2024 (GLOBE NEWSWIRE) -- NEW YORK -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path...
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
May 31, 2024 12:00 ET
|
Alberta Cancer Foundation
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
Local startup Oncobiotix
Dew Aesthetics Unveils Cutting-Edge MedSpa Treatments in Baltimore, Pioneering a Path to Timeless Beauty
May 15, 2024 10:00 ET
|
Dew Aesthetics
BALTIMORE, Md., May 15, 2024 (GLOBE NEWSWIRE) -- Dew Aesthetics, the premier destination for cutting-edge medical spa treatments, is proud to announce the launch of its innovative services,...
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
May 14, 2024 09:05 ET
|
GRI Bio, Inc.
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
May 08, 2024 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager,...
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
May 07, 2024 07:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...